Ars Live: The rise of GLP-1 drugs: Insights and Unknowns

Lizard venom launched the first drug

The first approved GLP-1 drug, exenatide (April 2005), originated from a peptide discovered in Gila monster venom that resisted degradation unlike native human GLP-1, which breaks down within minutes.

Not physiologically essential but pharmacologically powerful

Genetically modified mice lacking GLP-1 receptors maintain normal weight and glucose control, yet pharmaceutical doses of GLP-1 produce dramatic weight loss and diabetes remission through brain-based appetite suppression.

Triple mechanism drives benefits

Therapeutic effects stem from direct receptor activation in the heart, kidneys, and blood vessels; metabolic improvements from weight loss; and systemic anti-inflammatory actions mediated through gut immune cells and brain signaling.

Withdrawn drug still protected hearts

The Harmony Outcomes trial demonstrated that albiglutide—withdrawn from the market for weak diabetes and weight effects—reduced heart attacks, strokes, and cardiovascular deaths by 22%, proving cardiac benefits exist separate from metabolic improvements.

Weight loss amount doesn't determine cardiac benefit

The SELECT trial of semaglutide in 16,000 patients showed a 20% reduction in major cardiovascular events regardless of whether patients lost less than 5% or significantly more of their body weight.

Direct organ protection confirmed in animals

Mouse studies demonstrate GLP-1 drugs reduce heart attack size regardless of diabetes status or weight changes, confirming direct protective effects on cardiac and vascular cells independent of metabolic improvements.

Phase 3 trials underway for neurodegeneration

Following promising early data, final-stage clinical trials are testing GLP-1 drugs for Parkinson's and Alzheimer's diseases, with mechanisms potentially involving improved mitochondrial function, cellular communication, and reduced brain inflammation.

Glucagon combinations target liver disease

Triple-agonist therapies combining GLP-1 with glucagon (rather than just GIP) show particular promise for metabolic liver disease because glucagon acts directly on hepatic cells, potentially elevating these drugs as primary treatments for liver conditions.

Evolutionary role in gut defense

While not essential for modern metabolic control, GLP-1 likely evolved as a defense mechanism against intestinal infections, with levels rising tenfold during severe gut infections to suppress inflammation through T-cell regulation.

Oral and monthly injections coming

Next-generation delivery systems include oral tablets to address supply constraints, monthly or quarterly injectables for convenience, and experimental gene therapies that might eventually eliminate the need for ongoing injections.

Each new combination requires fresh safety validation

Despite 20 years of GLP-1 safety data, adding new components like glucagon or amylin to create multi-agonist drugs requires restarting safety monitoring, as risk profiles cannot be automatically extrapolated from existing medicines.

Weight maintenance possible for some after stopping

Contrary to assumptions that all weight returns, 46% of patients who stopped tirzepatide after 36 weeks maintained at least 10% weight loss after one year, though chronic conditions like heart disease likely require indefinite treatment.